Taking this into account, Robert W. Baird downgraded its Leap Therapeutics Inc [LPTX] rating to a Neutral from a an Outperform in a research note published on January 29, 2025; the price target was decreased to $1.25 from $9. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who decreased its forecast for the stock in late January from “a Buy” to “a Neutral”. Rodman & Renshaw began covering LPTX with “Buy” recommendation on June 28, 2024. Mizuho started covering the stock on October 04, 2021. It rated LPTX as “a Buy”.
Price Performance Review of LPTX
On Tuesday, Leap Therapeutics Inc [NASDAQ:LPTX] saw its stock fall -12.39% to $0.34. Over the last five days, the stock has lost -13.48%. Leap Therapeutics Inc shares have fallen nearly -88.34% since the year began. Nevertheless, the stocks have fallen -89.43% over the past one year. While a 52-week high of $4.79 was reached on 01/07/25, a 52-week low of $0.22 was recorded on 04/04/25. SMA at 50 days reached $0.3843, while 200 days put it at $1.9778.
Levels Of Support And Resistance For LPTX Stock
The 24-hour chart illustrates a support level at 0.3097, which if violated will result in even more drops to 0.2844. On the upside, there is a resistance level at 0.3707. A further resistance level may holdings at 0.4064. The Relative Strength Index (RSI) on the 14-day chart is 39.43, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0081, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.27%. Stochastics %K at 51.20% indicates the stock is a holding.
